PO.TB04.06 · 肿瘤生物学
In Vivo Models 1: Mouse, Zebrafish, and Alternative Species
-
-
-
-
-
-
-
-
-
- 2163 2163 对Enhertu®获得性耐药的三阴性乳腺癌PDX模型：揭示逃逸机制的临床前平台 Triple-negative breast cancer PDX models with acquired resistance to Enhertu ® : A preclinical platform to uncover mechanisms of escape Emilie INDERSIE, Benjamin GUERRIN, Eugenie DELHORBE, Eva CYPRIEN, Elena DARBINEAN, Delphine NICOLLE, Marie TAVERNIER, Olivier DÉAS
- 2164 2164 对olaparib获得性耐药的乳腺癌PDX模型：揭示PARP抑制剂逃逸机制的临床前平台 Breast cancer PDX models with acquired resistance to olaparib: A preclinical platform to uncover mechanisms of PARP inhibitor escape Emilie INDERSIE, Benjamin GUERRIN, Eugenie DELHORBE, Eva CYPRIEN, Elena DARBINEAN, Delphine NICOLLE, Marie TAVERNIER, Olivier DÉAS
-
-
-
-
- 2170 2170 患者来源原位异种移植模型预测胰腺导管腺癌的化疗应答：转化研究的新兴平台 Patient-derived orthotopic xenograft models predict chemotherapeutic response in pancreatic ductal adenocarcinoma: an emerging platform for translational research Xin Zhang, Nathan Bolton, Alicia Ray, Grace Maresh, Rachel Graham, Li Li
-
-
- 2173 2173 开发新型mHSPC和mCRPC同基因小鼠模型，用于评估放射性药物对免疫肿瘤微环境（TME）的影响 Development of novel syngeneic mouse models of mHSPC and mCRPC for evaluation of radiopharmaceuticals on the immune tumor microenvironment (TME) Brian Ragaishis, Andrei Molotkov, Shruti Bansal, Krishan Saini, Maierdan Palihati, Chelsea Rahiman, Courtney Buress, Jasleen Kaur Virk, Mikhail Doubrovin, Catherine Spina
- 2174 2174 一个全面的基于CRISPR/Cas9的RAS敲入细胞系平台（50余种模型），用于评估KRAS靶向抑制剂在RAS突变型恶性肿瘤中的疗效 A comprehensive CRISPR/Cas9-based RAS knock-in cell line platform (50+ models) for assessing efficacy of KRAS-targeted inhibitors in RAS-mutant malignancies. Lin Zhou, Guoqian Wang, Tingduo Lv, Zidan Su, Yue Huang, Jinying Ning, Feng Hao
-
- 2177 2177 来源于PARP抑制剂预处理的乳腺癌和卵巢癌患者的一组PDX模型的表征及其治疗评估 Characterization of a panel of PDX models derived from PARP inhibitors pretreated breast and ovarian cancer patients for therapeutic evaluation Qingzhi Liu, Jinxi Wang, Leilei Chen, Wubin Qian, Likun Zhang, Ludovic Bourre, Jessie Jingjing Wang
-
-
